Showing 7431-7440 of 9915 results for "".
- Merck Discontinues Testing of Experimental Skin Cancer Combo Therapyhttps://practicaldermatology.com/news/merck-discontinues-testing-experimental-skin-cancer-combo-therapy/2463022/Merck has announced the termination of the vibostolimab and pembrolizumab coformulation arm in the Phase 3 KeyVibe-010 trial, according to a news release from the company. The trial assessed the combination therapy's efficacy compared to KEYTRUDA alone as adjuvant treatment for patients w
- Allergan Calls for Real Patient Stories in New Campaignhttps://practicaldermatology.com/news/allergan-calls-real-patient-stories-new-campaign/2462879/Allergan Aesthetics has announced that it is inviting consumers to participate in upcoming campaigns for their flagship brands, including BOTOX® Cosmetic, the JUVÉDERM® collection of fillers. Both current and prospective patients can now apply for a chance to feature in future brand promo
- Palm Phytonutrients To Be Displayed at Expohttps://practicaldermatology.com/news/palm-phytonutrients-be-displayed-expo/2462663/As the cosmeceutical market continues to expand, so does consumer interest in learning more about the key active ingredients in cosmeceutical products and how they work, according to a press release from palm phytonutrient manufacturer PhytoGaia. PhytoGaia, a manufacturer of palm phytonut
- New Assessment Tool for Chronic Prurigo Shows Power of Patient Reportinghttps://practicaldermatology.com/news/development-and-validation-of-a-patient-reported-outcome-measure-to-assess-disease-control-in-chronic-prurigo/2462214/Researchers have introduced a 5-item Prurigo Control Test (PCT), in what could be the first patient-reported outcome measure for determining disease control for chronic prurigo (CPG). This tool, according to the researchers, was designed to assess disease control in CPG
- Vidac Queues Up Phase 2b Study for Potential Actinic Keratosis Therapyhttps://practicaldermatology.com/news/vidac-pharma-to-conduct-phase-2b-study-for-actinic-keratosis-therapeutic-candidate-vda-1102-with-centroderm/2462192/Vidac Pharma Holdings recently announced the commencement of a Phase 2b trial for its candidate therapy (VDA-1102) to treat actinic keratosis (AK), and has engaged with a research team from a leading clinical dermatology clinical research institute (CentroDerm GmbH). According to the ma
- Skin Cancer Combination Therapy Linked with Reduced Recurrence, Death: Studyhttps://practicaldermatology.com/news/merck-moderna-detail-potential-skin-cancer-vaccine-progress/2462183/Merck and Moderna
- Intradermal AIV001 Found Safe in Early BCC Studyhttps://practicaldermatology.com/news/intradermal-aiv001-found-safe-in-early-bcc-study/2462178/AiViva Biopharma Inc. completed its first trial administering AIV001 (axitinib) to patients diagnosed with basal cell carcinoma (BCC) tumors. AIV001 is intradermally administered and designed for local, prolonged treatment effect for dermatological conditions. The phase
- Cosmo, Glenmark Sign Distribution and License Agreements for Winlevi in Europe and South Africahttps://practicaldermatology.com/news/cosmo-glenmark-sign-distribution-and-license-agreements-for-winlevi-in-europe-and-south-africa/2462024/Glenmark Pharmaceuticals Ltd., now has exclusive rights to commercialize Winlevi (clascoterone cream 1%) in 15 EU countries (Bulgaria, the Czech Republic, Denmark, Finland, France, Hungary, Iceland, the Netherlands, Norway, Poland, Portugal,
- Arcutis Launches Educational Campaign for People Living with Seborrheic Dermatitishttps://practicaldermatology.com/news/arcutis-launches-educational-campaign-for-people-living-with-seborrheic-dermatitis/2462021/Arcutis Biotherapeutics, Inc. is launching
- AbbVie Awards 45 Scholarships to U.S. Students Living With Psoriasis, Eczema, and Other Chronic, Immune-Mediated Diseaseshttps://practicaldermatology.com/news/abbvie-awards-45-scholarships-to-us-students-living-with-psoriasis-eczema-and-other-chronic-immune-mediated-diseases/2461970/AbbVie announced the 2023-2024 class of